Experiences with

Alemtuzumab

In patients with demonstrated moderate-to-high-disease activity, early initiation of “high-efficacy” DMTs, such as fingolimod, monoclonal antibodies such as natalizumab and alemtuzumab and new generation monoclonal anti-CD20 antibodies such as ocrelizumab may help to better control the disease (Merkel

Some MS therapies, including steroids and disease-modifying therapies like Lemtrada (alemtuzumab), Tysabri (natalizumab), and Gilenya (fingolimod), are associated with diminished effectiveness of vaccines and a risk of infection as well.

Hi Has anyone been treated with the above medication (I have given both names for it). If you have how was it?and did it work for you? I think I am running out of drug options/ combinations now, and platelets remain at 0. This is the doctors next plan but the hospital have only ever treated 3 people

Hi Realise this is very specific but know from here and was also told on G2 (Infusion bay at Addenbrookes - formally PSSU) that there are a couple of other teachers out there whose Behcet's has been tackled with campath. I would love to link up. I've just finished my fourth course of campath yesterday

Question from the face book group if anyone can help Just wondering if anybody has had - Alemtuzumab Dr David Jayne has put me forwards for it. I have to wait until June, 6 months clear of Rituximab but hopefully I will finally be able to get things under control with this new one...

Martin Lockwood treated me with a drug then called Campath, (Alemtuzumab) at Addenbrooke’s Hospital Cambridge. I was suffering with Wegener’s Granulomatosis. Since then the Vasculitis Clinic at Addenbrooke’s now headed by Dr.

Coles, the first author of two papers describing phase 3 trials of alemtuzumab for Multiple Sclerosis.)

Lemtrada is another name for Alemtuzumab. This is the Wiki article on it: http://en.wikipedia.org/wiki/Alemtuzumab Rod Image is taken from Wiki article.

Alemtuzumab consolidation did not provide benefit over similar regimens without alemtuzumab, irrespective of age." Neil

Irradiated blood components should be used after alemtuzumab (anti-CD52) therapy. Their use after rituximab (anti-CD20) is not recommended at this time.

Alemtuzumab, aka Campath, ,consolidation therapy after chemotherapy or chemoimmunotherapy does not improve progression-free or overall survival in either younger or older patients.' Article...

VUK also play an active role in the UK Vasculitis Rare Disease Working Group In terms of current research funding, VUK are supporting trials at Addenbrookes Hospital, Cambridge of a new drug for the treatment of vasculitis, Alemtuzumab as well as a project at Birmingham Wellcome Trust Clinical Research

We have received an email today asking about Campath. This lady is about to start a course of treatment and is obviously very concerned.

Dr David Jayne's team led by Dr Rona Smith at Addenbrookes are undertaking research into an existing drug, Alemtuzumab, to see if it proves to be effective in treating ANCA related vasculitis. Alemtuzumab, which is one of the new generation of monoclonal antibodies, like Rituximab.